NCT07556133 Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
| NCT ID | NCT07556133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saint-Joseph University |
| Condition | Sedation |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-11-09 |
| Primary Completion | 2026-11-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2025-11-09 with a primary completion date of 2026-11-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults. The main questions it aims to answer are: * Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol? * How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure) * Are respiratory events more common in a certain group? * Is the surgeon's satisfaction similar among groups? * Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group? Researchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols. Participants will : * Receive one of these three protocols * Be operated for one or both eyes * Monitored during the whole surgery and in the recovery room * Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.
Eligibility Criteria
Inclusion Criteria: * Adults undergoing cataract surgery Exclusion Criteria: * Severe hepatic insufficiency * Third degree AV block * Patient refusal
Contact & Investigator
Naji Abou Jalad, MD
STUDY DIRECTOR
Hotel Dieu de France Hospital, Beirut, Lebanon
Frequently Asked Questions
Who can join the NCT07556133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sedation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07556133 currently recruiting?
Yes, NCT07556133 is actively recruiting participants. Contact the research team at rhea.nacouzi@net.usj.edu.lb for enrollment information.
Where is the NCT07556133 trial being conducted?
This trial is being conducted at Beirut, Lebanon.
Who is sponsoring the NCT07556133 clinical trial?
NCT07556133 is sponsored by Saint-Joseph University. The principal investigator is Naji Abou Jalad, MD at Hotel Dieu de France Hospital, Beirut, Lebanon. The trial plans to enroll 1,000 participants.